The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
Terstappen J. et al, (2024), Lancet Infect Dis, 24, e747 - e761
New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.
Mwanga MJ. et al, (2023), Emerg Infect Dis, 29, 2376 - 2379
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
Green C. et al, (2023), Clin Exp Immunol, 211, 269 - 279
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
Mazur NI. et al, (2023), Lancet Infect Dis, 23, e2 - e21
Development of a controlled human infection model to study respiratory syncytial virus infection in older adults
Sande CJ., (2022), The Lancet Healthy Longevity, 3, e370 - e371
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.
Carbonell-Estrany X. et al, (2022), Front Pediatr, 10
Enrichment approach for unbiased sequencing of respiratory syncytial virus directly from clinical samples.
Waweru JW. et al, (2021), Wellcome open research, 6
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Jefferies K. et al, (2020), J Infect Dis, 222, S658 - S665